Harpoon Therapeutics (FRA:5HTA) Debt-to-Equity : 3.19 (As of Sep. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Harpoon Therapeutics Debt-to-Equity?

Harpoon Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €2.79 Mil. Harpoon Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was €10.80 Mil. Harpoon Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2023 was €4.26 Mil. Harpoon Therapeutics's debt to equity for the quarter that ended in Sep. 2023 was 3.19.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Harpoon Therapeutics's Debt-to-Equity or its related term are showing as below:

FRA:5HTA' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.22 Med: 0.21 Max: 21.83
Current: 3.19

During the past 7 years, the highest Debt-to-Equity Ratio of Harpoon Therapeutics was 21.83. The lowest was -0.22. And the median was 0.21.

FRA:5HTA's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs FRA:5HTA: 3.19

Harpoon Therapeutics Debt-to-Equity Historical Data

The historical data trend for Harpoon Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harpoon Therapeutics Debt-to-Equity Chart

Harpoon Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.16

0.25

0.21

2.96

Harpoon Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-Equity	Get a 7-Day Free Trial															0.65	2.96	21.82	5.06	3.19

Competitive Comparison of Harpoon Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Harpoon Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Harpoon Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harpoon Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Harpoon Therapeutics's Debt-to-Equity falls into.

Harpoon Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Harpoon Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.287	+	12.822)	/	5.097
	=	2.96

Harpoon Therapeutics's Debt to Equity Ratio for the quarter that ended in Sep. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(2.787	+	10.804)	/	4.255
	=	3.19

Harpoon Therapeutics (FRA:5HTA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Harpoon Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Harpoon Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Harpoon Therapeutics (FRA:5HTA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harpoon Therapeutics Inc (FRA:5HTA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

HARP:USA

Address

131 Oyster Point Boulevard, Suite 300, South San Francisco, CA, USA, 94080

Website

https://www.harpoontx.com

Harpoon Therapeutics Inc is a clinical-stage immunotherapy company. It is engaged in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The company's pipeline products include HPN424, HPN536, HPN217, and others.

Harpoon Therapeutics (FRA:5HTA) Headlines

No Headlines